In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.

DW-116 is a novel fluoroquinolone that was two- to four-fold more active than rufloxacin and less active than sparfloxacin, ciprofloxacin and ofloxacin against Gram-positive bacteria in vitro. Against Gram-positive and Gram-negative bacteria, the in-vivo activity of DW-116 was similar or slightly greater than that of rufloxacin and less than that of sparfloxacin, ciprofloxacin and ofloxacin. ED50 (50% effective dose) values for DW-116 did not correlate with in-vitro MICs.

[1]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[2]  D. -. Kim,et al.  In-vitro and in-vivo activity of DWC-751, a new cephalosporin. , 1994, The Journal of antimicrobial chemotherapy.

[3]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[4]  V. Tullio,et al.  Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo and in-vivo results. , 1994, The Journal of antimicrobial chemotherapy.

[5]  H. Yoshida [Mechanisms of bacterial resistance to quinolones]. , 1996, Nihon saikingaku zasshi. Japanese journal of bacteriology.